Author

Ruize Gao

Luxembourg Institute of HealthORCID 0000-0002-3582-4726Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

Bassam JanjiiD· 2 shared Guy BerchemiD· 2 shared Kris Van Moer· 2 shared Akinchan Kumar· 1 shared Anaïs OudiniD· 1 shared Andy ChevignéiD· 1 shared Annette IvesiD· 1 shared Chenxi LiiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Bassam JanjiORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ACB1801 enhances tumor immunogenicity by targeting glycolysis/ferroptosis vulnerability and activating STAT1-signaling to overcome anti-PD-1 resistance in MSS colorectal cancer

Ruize Gao, Kris Van Moer, Coralie Pulido, Anaïs Oudin, Chenxi Li, Margaux Poussard, teresa L Ramos, Diane Murera, Elisabetta Bartolini, Annette Ives, Marine Gerbé de Thoré, Michele Mondini, Éric Deutsch, Guy Berchem, Christian Auclair, Bassam Janji

ACB1801 enhances anti-PD-1 therapy efficacy in MSS CRC by reprogramming the TME through metabolic reprogramming and STAT1 signaling activation.

bioRxiv · Feb 25, 2026 · PreprintCancer Biology

Targeting the Atypical Chemokine Receptor 2 (ACKR2) improves the benefit of anti-PD-1 immunotherapy in melanoma

Muhammad Zaeem Noman, Martyna Szpakowska, Malina Xiao, Ruize Gao, Kris Van Moer, Akinchan Kumar, Markus W. Ollert, Guy Berchem, Andy Chevigné, Bassam Janji

This study shows that targeting ACKR2 enhances anti-PD-1 immunotherapy efficacy in melanoma by improving the tumor microenvironment and immune cell infiltration.

OncoImmunology · Apr 18, 2025Peer-reviewedCancer Biology